Trials / Completed
CompletedNCT02704364
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM282 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2016-03-10
- Last updated
- 2025-06-17
- Results posted
- 2025-06-17
Locations
38 sites across 4 countries: United States, France, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT02704364. Inclusion in this directory is not an endorsement.